Sangamo Therapeutics stock sank Tuesday after the genomic medicine company said Pfizer had withdrawn from an agreement to develop a hemophilia drug. Shares of the California-based biotech ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data, following a pattern of big pharma partners ending collaborations. Current hemophilia A market ...

Williamsville struggled shooting against Auburn for a fifth straight quarter, but unlike the January Sangamon County ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease.

Auburn, IL. (WICS) — With their regular-season finale on Friday Williamsville finished the regular season undefeated in ...

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...